Treatment of murine lupus with TIGIT-Ig

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 203(2019) vom: 15. Juni, Seite 72-80
1. Verfasser:	Liu, Shuowu (VerfasserIn)
Weitere Verfasser:	Sun, Lizhu, Wang, Chuqi, Cui, Yingshu, Ling, Yuee, Li, Tian, Lin, Fangxing, Fu, Wenyan, Ding, Min, Zhang, Shuyi, Lei, Changhai, Hu, Shi
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2019
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Research Support, Non-U.S. Gov't Murine lupus Targeted therapy Tigit Antibodies, Antinuclear Immunoglobulin Fc Fragments Immunoglobulin G Receptors, Immunologic Recombinant Fusion Proteins T cell Ig and ITIM domain protein, mouse

Beschreibung
Zusammenfassung:	Copyright © 2019 Elsevier Inc. All rights reserved. The TIGIT (T cell immunoreceptor with Ig and ITIM domains) protein is a co-inhibitory receptor that has been reported to suppress autoreactive T and B cells to trigger immunological tolerance. We generated a new recombinant protein by connecting the extracellular domain of murine TIGIT to the Fc region of the mouse immunoglobulin IgG2a. The fusion protein was then characterized. The results suggested that among mice with lupus that were treated with the TIGIT-Ig fusion protein, the onset of proteinuria was delayed, serum concentrations of autoantibodies, such as antinuclear antibodies, were reduced without a decrease in the total IgG concentrations, and the survival rate was significantly increased compared to those of the controls. In conclusion, TIGIT-Ig administration showed promising results for both the prevention and treatment of autoimmune diseases in mice. This indicates that treatment with recombinant human TIGIT-Ig shows promise as an effective way to treat human autoimmune diseases
Beschreibung:	Date Completed 02.04.2020 Date Revised 02.04.2020 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-7035
DOI:	10.1016/j.clim.2019.04.007